Table of Contents
1 Stem Cell Therapy Market in Asia-Pacific to 2018 – Table of Contents
1.1 List of Figures
1.2 List of Tables
2 Stem Cell Therapy Market in Asia-Pacific to 2018 – Executive Summary
2.1 The Stem Cell Therapy Market in Asia-Pacific is in its Nascent Stage, but is Poised for Significant Growth in the Forecast Period
2.2 Companies Favor Licensing Agreements to Minimize the Risk of Uncertain Therapeutic Outcomes in Stem Cell Therapy
2.3 Emergence of Institutional Research
3 Stem Cell Therapy Market in Asia-Pacific to 2018 – Introduction
3.1 GBI Research Report Guidance
4 Stem Cell Therapy Market in Asia-Pacific to 2018 – Overview
4.1 Introduction
4.2 Market Characterization and Forecasts – Overview
4.2.1 Revenue Forecasts
4.2.2 Cost of Therapy
4.2.3 Allogeneic and Autologous Share
4.2.4 Stem Cell Therapy Patient Pool
4.3 Drivers and Barriers
4.3.1 Drivers
4.3.1.1 Favorable Regulation and Strong Government Support, with a Focus on Country-Specific Research to Address Unmet Needs
4.3.1.2 Strong Pipeline With 77% of Molecules in Phase II and Phase I/II
4.3.1.3 Marketed Products for the Treatment of Diseases such as AMI, CABG, Crohn’s Anal Fistula and Type 1 and 2 DM
4.3.1.4 Emergence of Public Research Laboratories and Hospitals
4.3.2 Barriers
4.3.2.1 Unknown Therapeutic Outcomes and Reproducibility Problems
4.3.2.2 Lack of Patient Awareness
5 Stem Cell Therapy Market in Asia-Pacific to 2018 – India
5.1 Introduction
5.2 Regulatory Landscape
5.3 Market Characterization and Forecasts – Overview
5.3.1 Revenue Forecasts
5.3.2 Cost of Therapy
5.3.3 Stem Cell Patient Pool
5.4 CABG Market Characterization and Forecasts
5.4.1 Introduction
5.4.2 Revenue Forecasts
5.4.3 Cost of Therapy
5.4.4 Stem Cell Patient Pool
5.5 Type 2 DM Market Characterization and Forecasts
5.5.1 Introduction
5.5.2 Revenue Forecasts
5.5.3 Cost of Therapy
5.5.4 Stem Cell Patient Pool
5.6 LSCT Market Characterization and Forecasts
5.6.1 Introduction
5.6.2 Revenue Forecasts
5.6.3 Cost of Therapy
5.6.4 Stem Cell Patient Pool
6 Stem Cell Therapy Market in Asia-Pacific to 2018 – China
6.1 Introduction
6.2 Regulatory Landscape
6.3 Market Characterization and Forecasts – Overview
6.3.1 Type 1 DM Market Characterization and Forecasts
6.3.1.1 Overview
6.3.1.2 Revenue Forecasts
6.3.1.3 Cost of Therapy
6.3.1.4 Stem Cell Patient Pool
7 Stem Cell Therapy Market in Asia-Pacific to 2018 – Japan
7.1 Introduction
7.2 Regulatory Landscape
7.3 Steroid Refractory aGvHD Market Characterization and Forecasts
7.3.1 Overview
7.3.2 Revenue Forecasts
7.3.3 Cost of Therapy
7.3.4 Stem Cell Patient Pool
8 Stem Cell Therapy Market in Asia-Pacific to 2018 – Singapore
8.1 Introduction
8.2 Regulatory Landscape
8.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002)
8.2.1.1 Overview
8.2.2 Human Tissue Research (November 2002)
8.2.2.1 Overview
8.2.3 Research Involving Human Subjects (November 2004)
8.2.3.1 Overview
8.2.4 Genetic Testing and Genetic Research (November 2005)
8.2.4.1 Overview
8.2.5 Personal Information in Biomedical Research (May 2007)
8.2.5.1 Overview
8.2.6 Donation of Human Eggs for Research (November 2008)
8.2.6.1 Overview
8.2.7 Human-Animal Combinations in Stem Cell Research (September 2010)
8.2.7.1 Overview
9 Stem Cell Therapy Market in Asia-Pacific to 2018 – South Korea
9.1 Introduction
9.2 Regulatory Landscape
9.3 Market Characterization and Forecasts – Overview
9.3.1 Revenue Forecasts
9.3.2 Cost of Therapy
9.3.3 Stem Cell Patient Pool
9.4 Cupistem Market Characterization and Forecasts
9.4.1 Overview
9.4.2 Revenue Forecasts
9.4.3 Cost of Therapy
9.4.4 Stem Cell Patient Pool
9.5 HCG-AMI Market Characterization and Forecasts
9.5.1 Overview
9.5.2 Revenue Forecasts
9.5.3 Cost of Therapy
9.5.4 Stem Cell Patient Pool
9.6 Cartistem Market Characterization and Forecasts
9.6.1 Overview
9.6.2 Revenue Forecasts
9.6.3 Cost of Therapy
9.6.4 Stem Cell Patient Pool
9.7 CCG Market Characterization and Forecasts
9.7.1 Overview
9.7.2 Revenue Forecasts
9.7.3 Cost of Therapy
9.7.4 Stem Cell Patient Pool
10 Stem Cell Therapy Market in Asia-Pacific to 2018 – Pipeline Analysis
10.1 Pipeline Analysis by Phase
10.2 Pipeline Analysis by Sponsors/Collaborators
10.3 Pipeline Analysis by Country
10.3.1 India Stem Cell R&D Pipeline
10.3.1.1 Overview
10.3.1.2 Phase II/III
10.3.1.3 Phase II
10.3.1.4 Phase I/II
10.3.1.5 Unknown
10.3.2 China Stem Cell R&D Pipeline
10.3.2.1 Overview
10.3.2.2 Post-Market
10.3.2.3 Phase II
10.3.2.4 Phase I/II
10.3.2.5 Phase I
10.3.2.6 Clinical Pre-Test
10.3.2.7 Unknown
10.3.3 Japan Stem Cell R&D Pipeline
10.3.3.1 Overview
10.3.3.2 Phase III
10.3.3.3 Phase II/III
10.3.3.4 Phase II
10.3.3.5 Phase I/II
10.3.3.6 Phase I
10.3.4 Singapore Stem Cell R&D Pipeline
10.3.4.1 Overview
10.3.4.2 Phase I/II
10.3.5 South Korea Stem Cell R&D Pipeline
10.3.5.1 Overview
10.3.5.2 Phase III
10.3.5.3 Phase II/III
10.3.5.4 Phase II
10.3.5.5 Phase I/II
10.3.5.6 Phase I
10.3.5.7 Unknown
10.3.6 Product Profiles of Promising Molecules
10.3.6.1 JR-031
10.3.6.2 CCG
10.3.7 Product Profiles of Marketed Products
10.3.7.1 HCG-AMI
10.3.7.2 Cartistem
10.3.7.3 CardioRel
10.3.7.4 Cupistem
10.3.7.5 ReliNethra
11 Stem Cell Therapy Market in Asia-Pacific to 2018 – Competitive Landscape
11.1 Stempeutics Research
11.1.1 Overview
11.1.2 Product Pipeline
11.2 Reliance Life Sciences
11.2.1 Overview
11.2.2 Product Pipeline
11.3 International Stem Cell Services
11.3.1 Overview
11.3.2 Product Pipeline
11.4 Shenzhen Beike Biotechnology
11.4.1 Overview
11.4.2 Product Pipeline
11.5 JCR Pharmaceuticals
11.5.1 Overview
11.5.2 Product Pipeline
11.6 ES Cells International (Subsidiary of BioTime, Inc)
11.6.1 Overview
11.6.2 Product Pipeline
11.7 Stem Cell Technologies i
11.7.1 Overview
11.7.2 Product Pipeline
11.8 Pharmicell
11.8.1 Overview
11.8.2 Product Pipeline
11.9 Medipost
11.9.1 Overview
11.9.2 Product Pipeline
12 Stem Cell Therapy Market in Asia-Pacific to 2018 – Strategic Consolidations
12.1 Overview
12.2 M&A Deals
12.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m – October 28, 2011
12.2.2 BioTime Acquired ES Cell International – May 3, 2010
12.2.3 BCCL Acquires Stake in Life Cell – May 1, 2007
12.3 Licensing Deals
12.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy – September 29, 2011
12.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR – January 4, 2011
12.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics – April 27, 2010
12.3.4 Teijin Enters into Licensing Agreement with SanBio – March 2, 2010
12.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma – September 9, 2009
12.3.6 Merck Signs a Licensing Agreement with Japan Tobacco – September 25, 2008
12.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences – January 31, 2007
12.4 Co-Development Deals
12.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal – September 13, 2011
12.4.2 Athersys Enters into Co-Development Agreement with Pfizer – December 21, 2009
12.4.3 Genzyme Enters into Agreement with Osiris Therapeutics – November 4, 2008
12.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma – December 21, 2007
13 Stem Cell Therapy Market in Asia-Pacific to 2018 – Appendix
13.1 Market Definitions
13.2 Abbreviations
13.3 Bibliography
13.4 Research Methodology
13.4.1 Coverage
13.4.2 Secondary Research
13.4.3 Primary Research
13.5 Therapeutic Landscape
13.5.1.1 Epidemiology-based Forecasting
13.5.2 Market Size by Geography
13.6 Geographical Landscape
13.7 Pipeline Analysis
13.8 Competitive Landscape
13.8.1 Expert Panel Validation
13.9 Contact Us
13.10 Disclaimer